Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision |
pharmaceutical_companies:ophirex [2022/04/16 05:48] liam [Staff] | pharmaceutical_companies:ophirex [2024/11/11 18:28] (current) liam [External links] |
---|
===== Affiliates ===== | ===== Affiliates ===== |
| |
| [[Derrick Rossi]], co-founder of [[pharmaceutical_companies:Moderna]], is an advisor to Ophirex.((Farooqui, S. (2021, July 6). //Moderna co-founder using mRNA technology to treat venomous snakebites.// Global News. https://archive.ph/URhV7)) |
| |
| ==== Funding ==== |
| |
| Ophirex is funded by multiple awards from the [[:US Department of Defense]], a grant from [[:Wellcome Trust]], and the [[:World Health Organization]].((Rao, S. (2020, March 2). //Ophirex receives Wellcome Trust award to advance clinical development of novel snakebite treatment.// Business Wire. https://archive.ph/LHsYv)) ((Karon, P. (2020). //Snakebites are a deadly threat worldwide. Who’s behind the push for a new treatment?// Inside Philanthropy. https://web.archive.org/web/20220413132035/https://static1.squarespace.com/static/5eb10eb62bf19e1bbec031bc/t/60c38b9ca1a11d3f55c2fb7d/1623427997415/Inside+Philanthropy+2020-12-17+Snakebites.pdf)) ((//Broad Spectrum Envenomation Treatment.// SBIR. Retrieved April 16, 2022, from https://archive.ph/T9toA)) |
==== Staff ==== | ==== Staff ==== |
| |
| Rebecca Carter | Vice President, Program Operations | | | Rebecca Carter | Vice President, Program Operations | |
| Kathleen Dotson | Vice President, Finance | | | Kathleen Dotson | Vice President, Finance | |
| | Dana Miletic | Operations Contracts Administrator | |
| | Jack Tupman | Executive | |
| | [[Sunita Rao]] | Senior Executive Administrator((//Sunita Rao.// LinkedIn. Retrieved April 15, 2022, from https://www.linkedin.com/in/sunitarao/)) | |
| |
===== Antivenom ===== | ===== Products ===== |
| |
In August 2017, Ophirex licensed varespladib from [[pharmaceutical_companies:Eli Lilly]] and [[pharmaceutical_companies:Shionogi]].((Lewin, M. (2017, August 28). //Ophirex Licenses Lilly - Shionogi Data for Novel Snakebite Treatment Development Program.// Bloomberg. https://archive.ph/5pvD3)) | ==== Antivenom ==== |
| |
==== BRAVO Study ==== | In August 2017, Ophirex licensed [[pharmaceutical_companies:varespladib]] from [[pharmaceutical_companies:Eli Lilly]] and [[pharmaceutical_companies:Shionogi]].((Lewin, M. (2017, August 28). //Ophirex Licenses Lilly - Shionogi Data for Novel Snakebite Treatment Development Program.// Bloomberg. https://archive.ph/5pvD3)) |
| |
| === COVID-19 === |
| |
| {{:pharmaceutical_companies:ophirex_stairs_trial_spot.png?150 |}} |
| |
| In 2020, Ophirex evaluated varespladib for treatment of [[:Acute Respiratory Distress Syndrome]] (ARDS), a common cause of death in [[:COVID-19]] patients. Despite the apparent winding down of the pandemic, their STAIRS trial continues.((Ophirex, Inc., & Premier Research International LLC. (2022, March 22). //A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Varespladib in Patients Hospitalized With Severe COVID 19 Caused by SARS-CoV-2.// ClinicalTrials.gov. https://archive.ph/jo7R9)) |
| |
| === BRAVO Study === |
| |
{{:pharmaceutical_companies:ophirex_bravo_trial_spot.jpeg?150 |}} | {{:pharmaceutical_companies:ophirex_bravo_trial_spot.jpeg?150 |}} |
| |
Ophirex is running a clinical trial titled "Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite (BRAVO)" in collaboration with [[Premier Research International]].((Ophirex, Inc., & Premier Research International LLC. (2022, February 9). //Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of a Multi-Dose Regimen of Oral Varespladib-Methyl in Subjects Bitten by Venomous Snakes.// ClinicalTrials.gov. https://archive.ph/xNuHy)) | Ophirex is running a clinical trial titled "Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite (BRAVO)" in collaboration with [[:Premier Research International]].((Ophirex, Inc., & Premier Research International LLC. (2022, February 9). //Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of a Multi-Dose Regimen of Oral Varespladib-Methyl in Subjects Bitten by Venomous Snakes.// ClinicalTrials.gov. https://archive.ph/xNuHy)) |
| |
| ===== External links ===== |
| |
| * [[https://wiki.whiteroseintelligence.com/en/Ophirex|White Rose Wiki]] |